Home › Identities › Transfeminine

Transfeminine

Transfeminine is a euphemistic intermediate layer—a spectrum umbrella over trans woman that avoids the sharp claim "I am a woman" while simultaneously lumping clinically distinct subgroups together under a single label. It obscures Blanchard's typology and hides the fact that AGP is a paraphilia, not an identity. Anyone who names the distinction is silenced.

Definition according to proponents

A person of male sex at birth with a female or feminine self-image at any point on the spectrum. Includes trans women, non-binary feminine persons, crossdressers with an identity claim, and persons with partial identification. The umbrella does not carry a diagnostic criterion of its own; it is a collective label for disparate subgroups.

Origin: 2010+ spectrum jargon

Spectrum terminology from 2010, dominant in activist literature and media guides from circa 2015. Strategically useful for the heterogeneous M-to-F population: it obscures the sharp dividing lines that Ray Blanchard distinguished between early-onset homosexual and late-onset autogynephilic. See Blanchard typology .

Anne Lawrence (2013) has empirically documented that a significant portion of the late-transitioned M-to-F population has autogynephilia as a driving factor — a paraphilia, not an identity. J. Michael Bailey (2003) and Blanchard (2005) described this pattern earlier and consistently. The term 'spectrum' deprives clinicians, policymakers, and the public of the ability to name this subgroup separately.

Criticism: euphemism as dogma

By placing late-onset M-to-F and early homosexual M-to-F individuals under a single spectrum label, the possibility of investigating their different epidemiologies, life trajectories, and risk profiles separately is lost. For policy (sports, prisons, single-sex facilities), this is inevitably problematic: a single rule is created for groups that are in fact not comparable. A textbook example of circular reasoning — identity explains identity — and of unfalsifiability . There is no marker , only self-reporting .

The Cass Review (2024) points out the broader care problem: without distinction between subgroups, treatment outcomes cannot be measured. Levine (2022) warns that the spectrum umbrella washes away clinically relevant variation and undermines informed consent. Helen Joyce (2021) points out the legal consequences — legislation that treats "transfeminine" as a protected category can undermine the safety interests of women in single-sex environments. Biggs (2022) has empirically documented this for English prisons. Criticism is dismissed as hate.

Damage: hormones, mammoplasty, vaginoplasty

Clinical pathways under the transfeminine umbrella vary widely: hormone therapy, mammoplasty, vaginoplasty, and/or voice training. Cass (2024) and SBU (2022) recommend caution regarding procedures under the age of 25; in adults, the evidence base remains weaker than is often presented. Hruz (2020) points out that irreversible interventions on healthy tissue do not meet standard evidence-based standards without objective diagnostics. Transition does not cure — see detransition research and regret research .

Related identities

• Trans woman — scarier claim.

• Non-binary — umbrella.

• Demigender — partial variant.

• Transgender — broad umbrella.

Frequently Asked Questions